Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Aytu BioScience to hold a special shareholder meeting » 11:25
01/24/20
01/24
11:25
01/24/20
11:25
AYTU

Aytu BioScience

$0.84 /

+0.01 (+1.20%)

Special Shareholder…

Special Shareholder Meeting to approve a proposal of the convertibility of the Company's Series F convertible preferred stock will be held in Englewood, CO on January 24 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Aytu BioScience to hold a special shareholder meeting » 04:55
01/24/20
01/24
04:55
01/24/20
04:55
AYTU

Aytu BioScience

$0.83 /

+0.0013 (+0.16%)

Special Shareholder…

Special Shareholder Meeting to approve a proposal of the convertibility of the Company's Series F convertible preferred stock will be held in Englewood, CO on January 24 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
Aytu BioScience to hold a special shareholder meeting » 15:48
01/18/20
01/18
15:48
01/18/20
15:48
AYTU

Aytu BioScience

$0.80 /

+0.0014 (+0.18%)

Special Shareholder…

Special Shareholder Meeting to approve a proposal of the convertibility of the Company's Series F convertible preferred stock will be held in Englewood, CO on January 24 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Syndicate
Aytu BioScience files to sell 20M shares of common stock for holders  16:19
12/17/19
12/17
16:19
12/17/19
16:19
AYTU

Aytu BioScience

/

+

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Aytu BioScienceAytu BioScience management to meet with Ladenburg » 04:55
12/04/19
12/04
04:55
12/04/19
04:55
AYTU

Aytu BioScience

$0.84 /

+0.0206 (+2.51%)

Meetings to be held in…

Meetings to be held in Boston on December 3 and in New York on December 4 hosted by Ladenburg.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Aytu BioScienceAytu BioScience management to meet with Ladenburg » 04:55
12/03/19
12/03
04:55
12/03/19
04:55
AYTU

Aytu BioScience

$0.82 /

-0.0156 (-1.87%)

Meetings to be held in…

Meetings to be held in Boston on December 3 and in New York on December 4 hosted by Ladenburg.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Aytu BioScience announces launch of Natesto U.S. co-promotion with Acerus » 08:07
12/02/19
12/02
08:07
12/02/19
08:07
AYTU

Aytu BioScience

$0.84 /

+0.0039 (+0.47%)

Aytu BioScience announced…

Aytu BioScience announced the launch of the company's co-promotion with Acerus Pharmaceuticals which is expected to accelerate the growth of in the United States. Through this expanded commercial relationship, Acerus has launched a U.S.-based specialty sales force promoting Natesto to urologists and endocrinologists. Aytu will continue to recognize all Natesto revenue and promote Natesto to all other physician specialties including internal medicine and family practice. Natesto total prescriptions grew 30% from fiscal 2018 to 2019, and this commercial partnership is expected to accelerate brand growth through joint promotional efforts and a significantly expanded U.S. presence. The Natesto co-promotion officially closed November 29 and was effective December 1. This agreement significantly increases sales force coverage of targeted testosterone prescribers and puts a higher promotional focus on urologists and endocrinologists. Further, this revised partnership enables Aytu to increase its Natesto promotional efforts in primary care and other specialties. To accelerate the launch of Acerus' U.S. commercial team, Aytu has agreed to transfer five current sales employees to Acerus as of December 2. These staff will operate as Acerus employees, but they will remain on Aytu's payroll until the earlier of the date on which Acerus is ready to fully assume the personnel or June 30, 2020. Aytu will deduct the costs of these sales personnel from quarterly payments otherwise owed to Acerus under the revised agreement, with a final accounting to be done once per year. Throughout 2020, Acerus will be building out a complete US-based specialty sales force and other commercial functions, significantly increasing the number of employees working directly on Natesto in the United States. As previously announced on July 30, the companies signed an agreement to expand their commercial partnership and amend and restate the original 2016 Natesto exclusive U.S. license agreement. Under the revised agreement, Aytu will remain the exclusive U.S. supplier of Natesto and retain all rights to revenues generated. Aytu and Acerus will continue to operate a joint commercialization committee in support of Natesto and will closely collaborate on U.S. brand strategy and commercial initiatives.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Aytu BioScienceAytu BioScience management to meet with Ladenburg » 07:07
12/02/19
12/02
07:07
12/02/19
07:07
AYTU

Aytu BioScience

$0.84 /

+0.0039 (+0.47%)

Meetings to be held in…

Meetings to be held in Boston on December 3 and in New York on December 4 hosted by Ladenburg.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Cerecor closes sale of pediatric portfolio to Aytu BioScience for $43M » 06:34
11/04/19
11/04
06:34
11/04/19
06:34
CERC

Cerecor

$3.46 /

+0.02 (+0.58%)

, AYTU

Aytu BioScience

$1.03 /

-0.01 (-0.96%)

Cerecor (CERC) announced…

Cerecor (CERC) announced that it has closed the sale of its pediatric portfolio of assets with AYTU BioScience (AYTU) in a deal valued in excess of $43M including the assumption of various liabilities and product-related obligations. The consideration includes a combination of cash and Aytu preferred stock totaling $17M and the assumption of Cerecor's outstanding payment obligations payable to Deerfield CSF in the amount of $15M and certain other liabilities in excess of $11M, providing non-dilutive cash generation for Cerecor. The funds from the transaction, coupled with the removal of the aforementioned short-term obligations, extend the runway toward NDA submission of CERC-801 and its associated Priority Review Voucher. Overall deal valued in excess of $43M as a composite of $17M in cash and preferred stock, the assumption of the Deerfield Note of $15M, the assignment of the existing royalty obligations coupled with various commercial accruals of $11M. Cash has been paid, and the Shares were issued at closing; the Shares are subject to customary lock-ups and are convertible to common shares following Aytu stockholder approval and immediately prior to their sale or distribution.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
Hot Stocks
Aytu BioScience reports addition of Tuzistra XR to national PBM formulary » 07:03
10/21/19
10/21
07:03
10/21/19
07:03
AYTU

Aytu BioScience

$1.20 /

-0.04 (-3.23%)

Aytu BioScience announced…

Aytu BioScience announced that Tuzistra XR is now on formulary and covered nationwide by a leading national pharmacy benefit manager. This PBM contract provides for unrestricted patient access to Tuzistra XR across the PBM's national commercial formularies. Over thirty million U.S. lives are covered by these commercial plans. Josh Disbrow, CEO of Aytu BioScience stated, "The addition of Tuzistra XR to this large, national PBM's formulary is an important step in building Tuzistra XR into a leading antitussive brand in the United States. This is a significant development as over 30 million commercially-insured patients have now gained access to Tuzistra XR. This positions Tuzistra XR well as Aytu enters the first full cough cold season since acquiring exclusive rights to the product last year. Also, with the recent addition of co-promote partner Poly Pharmaceuticals' thirty-person sales force, we believe this increased scale and improved coverage will further solidify Tuzistra XR's potential to become a leading product in the prescription antitussive category."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.